ClinicalTrials.Veeva

Menu

Walnuts for Cardiorenal Protection in Adults With Chronic Kidney Disease (NutReCard)

P

Pere Virgili Health Research Institute (IISPV)

Status

Enrolling

Conditions

Cardiovascular Biomarkers
Renal Function
CKD - Chronic Kidney Disease

Treatments

Other: Daily Walnut Consumption

Study type

Interventional

Funder types

Other

Identifiers

NCT07851454
PI25/01680

Details and patient eligibility

About

To date, no rigorous randomized controlled trials have demonstrated a protective effect of daily moderate walnut consumption on kidney function or chronic kidney disease (CKD) progression in individuals with CKD.

Objective: To determine the effect of walnut supplementation (30 g/day of raw walnuts) within a Mediterranean diet (MedDiet) based dietary counseling program, compared with the same MedDiet counseling program without walnut supplementation, on kidney function, CKD progression and regression, and classical and emerging cardiovascular risk markers in individuals with CKD. Secondary objectives focus on assessing whether regular walnut consumption as a healthy snack has a positive impact on inflammation, oxidative stress, endothelial dysfunction, and intestinal dysbiosis, conditions intrinsically linked to CKD that play a pathophysiological role in promoting/exacerbating its progression and the development of comorbidities in this vulnerable group of subjects.

Methodology: A 6-month randomized controlled trial will be conducted in 150 men and women aged 45 to 75 years with stable mild to moderate CKD (stage G3a-b), overweight or obesity, and high cardiometabolic risk. The study will compare the effect of two interventions assessed at 3 and 6 months on the following outcomes:

  1. Primary outcomes: a) changes in kidney function assessed by the Estimated Glomerular Filtration Rate based on creatinine and cystatin C (eGFRcr-cys); b) CKD progression; and c) CKD remission
  2. Secondary outcomes: a) urinary albumin-to-creatinine ratio (UACR); b) mineral and bone metabolism parameters, c) anthropometry and body composition (Dual-Energy X-ray Absorptiometry, DXA); d) bone mineral density (DXA); e) diet quality; f) physical activity; g) medication use; h) psychological well-being; i) quality of life; j) classic cardiovascular risk markers; k) iron status and hepatic function; l) inflammation, endothelial function, and oxidation markers; m) gut microbiota

Enrollment

150 estimated patients

Sex

All

Ages

45 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Men and women with stable mild to moderate chronic kidney disease [CKD] (stage G3a-b (estimated glomerular filtration rate [eGFR] 30-<60mL/min/1.73 m²) and albuminuria stages A1-3 (UACR from < 30mg/g to ≥ 300 mg/g))

  • 45-75 years old at screening

  • Overweight/obesity (Body Mass Index [BMI] ≥25 and ≤40 kg/m²)

  • Meet at least one of the following conditions:

    (i) Systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg, or use of antihypertensive agents (ii) Triglycerides ≥150 mg/dL, LDL cholesterol ≥160 mg/dL, HDL cholesterol ≤40 mg/dL in men or ≤50 mg/dL in women, or use of lipid-modifying medication (iii) Prediabetes or type 2 diabetes according to the American Diabetes Association (ADA) Standards, or use of glucose-lowering medication.

Exclusion criteria

  • Inability to give written informed consent
  • CKD caused by polycystic kidney disease, chronic pyelonephritis, and renal dysplasia
  • CKD on renal replacement therapy (hemodialysis, peritoneal dialysis, and kidney transplant recipients)
  • Acute exacerbation of CKD, whether due to extrarenal causes (decompensated heart failure, infectious disease or sepsis, surgical intervention) or due to an outbreak of underlying glomerular or systemic renal pathology, with changes in treatment in the last 2 months.
  • Nut allergy
  • Alcoholism (>50 g/day) or drug abuse
  • Treatment with immunosuppressant drugs or cytotoxic agents
  • Any other medical condition that interferes with the completion of the protocol (pregnancy/breastfeeding, history of inflammatory bowel disease, liver failure, cancer or active neoplasms, psychiatric problems)
  • Institutionalization of the participant.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

150 participants in 2 patient groups

Daily Walnut Consumption
Experimental group
Description:
Participants in the intervention group will consume 30 g/day of raw walnuts in addition to receiving a Mediterranean diet (MedDiet)-based dietary counseling program. To ensure and facilitate adherence, participants will receive two educational leaflets: one providing practical guidance on following a MedDiet and another containing MedDiet-compatible recipes incorporating walnuts. They will also receive written guidance on optimizing phosphorus and potassium intake within a Mediterranean dietary pattern, including information on food sources, hidden additives, and cooking techniques that may reduce mineral content. Walnuts will be provided free of charge and distributed at baseline and at each follow-up visit.
Treatment:
Other: Daily Walnut Consumption
Control: MedDiet-based dietary counseling
No Intervention group
Description:
Participants in the control group will receive the same MedDiet-based dietary counseling without walnut supplementation.

Trial contacts and locations

1

Loading...

Central trial contact

Andrés Díaz López, PhD; Verónica Ruíz García, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems